<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267380</url>
  </required_header>
  <id_info>
    <org_study_id>A3921359</org_study_id>
    <nct_id>NCT04267380</nct_id>
  </id_info>
  <brief_title>A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day</brief_title>
  <official_title>Compare Effectiveness of Tofacitinib 11 mg QD to Tofacitinib 5 mg BID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that patients prescribed tofacitinib 11 mg Modified Release (MR)
      formulation once daily (QD) will achieve similar benefit to those prescribed tofacitinib 5 mg
      twice a day (BID) dosage in real world use. This study will therefore seek to compare the
      effectiveness of the MR 11 mg QD regimen to the IR 5 mg BID regimen for the treatment of RA
      in a real-world registry of RA patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Minimally clinically important difference in improvement defined by difference in Clinical Disease activity index</measure>
    <time_frame>must have a follow-up visit at 6 months (+/- 3 months)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Arthritis Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Corrona US RA Registry 11 mg</arm_group_label>
    <description>patients with RA who have been exposed to tofacitinib 11 mg QD tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corrona US RA Registry 5 mg</arm_group_label>
    <description>patients with RA who have been exposed to tofacitinib 5 mg BID tablet</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients prescribed Tofacitinib in routine clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All US Corrona RA Registry patients who initiated tofacitinib 5 mg twice a day (BID)
             or tofacitinib 11 mg once daily (QD) after it became available in February 2016

          -  Patients must have a follow-up visit at 6 months (+/- 3 months) after tofacitinib
             initiation. These 6 month visits are part of routine practice and is not associated
             with this protocol.

          -  Patients must have a valid clinical disease activity index (CDAI) at initiation and at
             6-month follow-up visit

        Exclusion Criteria:

          -  There are no exclusion criteria for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

